GlassScriptPhysician profile
Jimmy Aleman
NPI 1679809024
$2,247.57
in general payments reported to CMS, 2019-2025
22 companies · $117 in 2025
The $117 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $964 · 2023: $948 · 2024: $219 · 2025: $117.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,218 · Education: $65.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,218.02 |
| Education | $65.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $632.75 | 2022-2025 | Wegovy, Ozempic, Rybelsus |
| Abbvie INC. | $274.88 | 2022-2023 | |
| Astellas Pharma US INC | $218.31 | 2023 | Veozah, Myrbetriq |
| Sanofi-Aventis U.S. LLC | $207.13 | 2022-2024 | |
| Biohaven Pharmaceutical Holding Company LTD. | $155.66 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $142.18 | 2022-2023 | |
| Glaxosmithkline, LLC. | $79.09 | 2022-2023 | Trelegy Ellipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $66.92 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $66.03 | 2022 | |
| Dexcom, INC. | $60.22 | 2022-2023 | Dexcom G6 Transmitter |
| Janssen Pharmaceuticals, INC | $50.46 | 2022-2023 | Xarelto |
| Pfizer INC. | $47.16 | 2022-2023 | |
| Lilly USA, LLC | $45.43 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $36.83 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $32.64 | 2023 | Rexulti |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $27.30 | 2022 | |
| Amgen INC. | $23.00 | 2022 | |
| Lundbeck LLC | $22.33 | 2022 | |
| Merck Sharp & Dohme LLC | $17.79 | 2023 | Dificid |
| Organon LLC | $15.32 | 2025 | Nexplanon |
| Nestle Healthcare Nutrition INC. | $14.20 | 2023 | |
| Novartis Pharmaceuticals Corporation | $11.94 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jimmy Aleman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.